A Harvard Medical School research team developed a bifunctional therapeutic vaccine strategy by transforming living tumor cells into a potent agent with direct tumor killing and immunostimulatory abilities.
Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical (Shanghai) Ltd. have synthesized antibody-drug conjugates consisting of an antibody covalently linked to exatecan derivatives through a linker.
The advent of bispecific antibodies bridging two different cell types has enabled a new level of cell specificity in cancer biology that has only recently begun to be realized in the clinic.
Researchers at GM Biosciences Inc. have reported developed a novel CD38xCD3 bispecific IgM T-cell engager IGM-2644 with 10 binding sites for human CD38 (Kd=0.27nM; measured by biolayer interferometry) and one anti-CD3 site (Kd=2.1nM) designed to reduce safety concerns.
Ammax Bio Inc. has entered into an exclusive option with Evopoint Biosciences Co. Ltd. for a worldwide license, excluding Greater China, for the development and commercialization of a novel antibody-drug conjugate (ADC) for treating solid tumors.
Aptevo Therapeutics Inc. has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 bispecific antibody, APVO-711, with the potential to treat a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma and carcinomas of the lung, gastrointestinal tract and colon.
Boehringer Ingelheim Pharma GmbH & Co. KG and 3T Biosciences Inc. have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet needs.
Researchers from Nordic Nanovector ASA presented the discovery of a novel humanized anti-CD37 monoclonal antibody, NNV-024, engineered to exhibit a strong antibody-dependent cellular cytotoxicity (ADCC).
Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a novel oncolytic virus (OV) for intravenous administration in patients with advanced non-small-cell lung cancer (NSCLC). Enrollment is expected to open in the first half of this year.
PDX Pharmaceuticals Inc.'s ARAC-02 has been selected to enter the Nanotechnology Characterization Laboratory (NCL)'s Assay Cascade Characterization Program.
RSS
